RxDoctor Payments Data

Alex Kuryan, MD

Gastroenterology · West Chester, PANPI 1669431425

Payments from drug & device makers

$11,502in general payments, 2019–2025

Across 590 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Johnson & Johnson$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$931
  • Takeda Pharmaceuticals U.S.A., Inc.$842
  • Bristol Myers Squibb$627
  • Sanofi$473
  • plus $5K from 37 others

What the payments were for

  • Consulting fees$3333%
  • Speaking & faculty fees$5505%
  • Food & beverage$10,57992%
  • Education$400%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,502 in reported general payments places this provider in the 75th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$205,753
Medicare patients
626
Services billed
3,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab14$358,951
Mesalamine ErMesalamine17$16,880
Mesalamine20$11,481
Balsalazide Disodium20$7,488
Dexlansoprazole DrDexlansoprazole13$5,806
ClenpiqSod Picosulf/Mag Ox/Citric Ac25$4,289
Pantoprazole Sodium236$3,543
Budesonide EcBudesonide15$2,533
Mercaptopurine15$2,508
Omeprazole234$2,496
Esomeprazole Magnesium16$1,324
Lansoprazole42$1,074
Famotidine57$1,022
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates12$838
Rabeprazole Sodium15$632

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,493$358,95114 claims
Ferring Pharmaceuticals Inc.Clenpiq$333$4,28925 claims
SandozLansoprazole$13$1,07442 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in West Chester

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →